Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir
暂无分享,去创建一个
Gerd Mikus | Walter E Haefeli | W. Haefeli | G. Mikus | J. Burhenne | T. Thomsen | Jürgen Burhenne | Johanna Weiss | J. Weiss | K. Riedel | Klaus-Dieter Riedel | Jens Rengelshausen | Reinhard Ding | Verena Schöwel | Magdalena Drzewinska | Torben Thomsen | J. Rengelshausen | V. Schöwel | R. Ding | Magdalena Drzewinska
[1] D. Greenblatt,et al. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir , 2006, Clinical pharmacology and therapeutics.
[2] N. Wood,et al. Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities , 2006, Journal of clinical pharmacology.
[3] A. Takagi,et al. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. , 2005, Biological & pharmaceutical bulletin.
[4] W. Haefeli,et al. Opposite effects of short‐term and long‐term St John's wort intake on voriconazole pharmacokinetics , 2005, Clinical pharmacology and therapeutics.
[5] C. Ernest,et al. Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors , 2005, Journal of Pharmacology and Experimental Therapeutics.
[6] R. Labadie,et al. Pharmacokinetic interaction between voriconazole and ritonavir at steady state in healthy subjects , 2005 .
[7] B. Clotet,et al. Steady-State Pharmacokinetics of a Double-Boosting Regimen of Saquinavir Soft Gel plus Lopinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Infected Adults , 2004, Antimicrobial Agents and Chemotherapy.
[8] M. Nakashima,et al. Pharmacokinetics of Voriconazole and Cytochrome p450 2C19 Genetic Status , 2004, Clinical pharmacology and therapeutics.
[9] A. Groll,et al. Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation. , 2003, The Journal of antimicrobial chemotherapy.
[10] N. Wood,et al. No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. , 2003, British journal of clinical pharmacology.
[11] N. Wood,et al. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. , 2003, British journal of clinical pharmacology.
[12] N. Wood,et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. , 2003, British journal of clinical pharmacology.
[13] N. Wood,et al. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. , 2003, British journal of clinical pharmacology.
[14] D. Back,et al. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. , 2003, British journal of clinical pharmacology.
[15] T. Kuijpers,et al. Liver failure in a child receiving highly active antiretroviral therapy and voriconazole. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] M. Rinaldi,et al. Development and Validation of a High-Performance Liquid Chromatography Assay for Voriconazole , 2003, Antimicrobial Agents and Chemotherapy.
[17] D A Smith,et al. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[18] N. Wood,et al. Safety of voriconazole and dose individualization. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] M. Pai,et al. Voriconazole inhibition of tacrolimus metabolism. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] D. Greenblatt,et al. Short‐Term Exposure to Low‐Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone , 2003, Journal of clinical pharmacology.
[21] Nina Singh,et al. Voriconazole Inhibition of the Metabolism of Tacrolimus in a Liver Transplant Recipient and in Human Liver Microsomes , 2002, Antimicrobial Agents and Chemotherapy.
[22] E. Thiel,et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] J. Goldstein,et al. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. , 2001, British journal of clinical pharmacology.
[24] D. Greenblatt,et al. Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir , 2000, Journal of acquired immune deficiency syndromes.
[25] D. Greenblatt,et al. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole , 2000, European Journal of Clinical Pharmacology.
[26] J. Kuper,et al. Drug Interactions of HIV Protease Inhibitors , 1999, Drug safety.
[27] J. Leonard,et al. Pharmacokinetic interaction between ritonavir and clarithromycin * , 1998, Clinical pharmacology and therapeutics.
[28] P. Vouros,et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[29] J. Leonard,et al. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin * , 1998, Clinical pharmacology and therapeutics.
[30] S. Piscitelli,et al. Protease inhibitors for the treatment of human immunodeficiency virus infection. , 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[31] William D. Dupont,et al. PS power and sample size program available for free on the internet , 1997 .
[32] J. Leonard,et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects , 1997, Antimicrobial agents and chemotherapy.
[33] A. D. Rodrigues,et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.
[34] M. Huang,et al. Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs , 2005, Clinical pharmacokinetics.
[35] C. Ernest,et al. Mechanism-Based Inactivation of CYP 3 A by HIV Protease Inhibitors , 2005 .
[36] T. Walsh,et al. Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. , 2004, Drugs.
[37] T. Kaminuma,et al. Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. , 2003, Drug metabolism and pharmacokinetics.
[38] D. Flockhart,et al. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.
[39] P. Vouros,et al. OF THE HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITORS INDINAVIR AND RITONAVIR BY HUMAN INTESTINAL MICROSOMES AND EXPRESSED CYTOCHROME P 4503 A 4 / 3 A 5 : MECHANISM-BASED INACTIVATION OF CYTOCHROME P 4503 A BY RITONAVIR , 1998 .